Menu Search
Equities

Matinas BioPharma Holdings Inc

6LJ:BER

Matinas BioPharma Holdings Inc

Actions
  • Price (EUR)0.1731
  • Today's Change0.003 / 2.00%
  • Shares traded0.00
  • 1 Year change-66.39%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 19:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology (LNC Platform). Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options. It is expanding the utilization of the LNC Platform with small molecules and small oligonucleotides outside of infectious disease, targeting inflammation and oncology. It is also investigating a variety of LNC formulations of two small oligonucleotides designed to target inflammatory cytokines IL-17A and TNFα.

  • Revenue in USD (TTM)1.10m
  • Net income in USD-22.94m
  • Incorporated2013
  • Employees32.00
  • Location
    Matinas BioPharma Holdings IncSuite 302, 1545 Route 206 SouthBEDMINSTER 07921United StatesUSA
  • Phone+1 (908) 443-1860
  • Fax+1 (302) 636-5454
  • Websitehttps://www.matinasbiopharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.